Astra Zeneca (Israel) Ltd

Aromatase Inhibitor. Anastrozole 1 mg.
TABS: 28. Adults and elderly: 1 tab. dly.
Advanced breast cancer in post-menopaus.
women. Adjuv. tmt of
postmenopaus. women with hormone
receptor-positive early invasive breast
cancer. Adjuv. tmt. early breast cancer in
hormone receptor +tive postmenopaus.
women who have received 2-3 yrs.
adjunct. tamoxifen.
C/I: Severe ren. impair., mod. or severe
hepat. dis., pregn., lact.

Angiotensin II Antagonist. Candesartan Cilexetil 4 mg, 8 mg, 16 mg.
TABS: 28 x 8 mg, 16 mg. Initial: 8 or 16
mg 1 x dly. Maint: 8 or 16 mg 1 x dly,
with or without food. Max. effect: 4
wks.
Hypertens.
C/I: Hypersens., pregn., lact.

Angiotensin II Antagonist, Diuretics. Candesartan Cilexetil 16 mg, Hydrochlorothiazide 12.5 mg.
TABS: 28. 1 tab x dly with or without
food. Elderly: No special dosage. Use
in pts with impair. ren. fusal: see lit.
Not recommend. for child.
Antihypertens. effect usually attained
within 4 wks.
Essent. hypertens. where monother. with
candesartan cilexetil or HCTZ is not
suffic.
C/I: Hypersens., severe ren. impair.,
severe hepat. impair and / or cholestas.,
gout.

Antiplatelet Agent. Ticagrelor 60 mg, 90 mg.
F.C. TABS: 56. Pts. taking Ticagrelor should also take ASA dly., unless specific. contraind.
Follow. an init. dose of ASA, Ticagrelor should be used with a mainten. dose of ASA of 75-150 mg.
Acute coron. syndr.: Ticagrelor tmt. should be initi. with a single 180 mg load. dose (2 tabs. of 90 mg) and then contin. at 90 mg ×2/d.
Tmt. with Ticagrelor 90 mg ×2/d is recomm. for up to 12 mnths. in ACS pts. unless discont. is clinic. indic.
Ticagrelor 60 mg ×2/d dly. is the recomm. dose when an extend. tmt. is requir. for pts. with a hist. of MI of at least 1 year and a high risk of an atherothrombot. event. Tmt. may be started without interrupt. as contin. ther. after the init. 1 -year tmt. with Ticagrelor 90 mg or other adenosine diphosphate (ADP) recept. inhib. ther. in ACS pts. with a high risk of an atherothrombot. event. Tmt. can also be init. up to 2 yrs. from the MI, or within 1 year after stop. prev. ADP recept. inhibit. tmt.
In pts. with ACS, premat. discont. with any antiplat. ther., includ. Ticagrelor, could result in an incr. risk of cardiovasc. death, or MI due to the pt’s. underlying dis. Therefore, premature discont. of tmt. should be avoided. See lit.
Indic. co-admin. with ASA, is for the preven.  of atherothrombot. events in adult pts. with - acute coron. syndr. (ACS) or - a hist. of MI and a high risk of develop. an atherothrombot.
Limitations of use: 90 mg ×2/d during the 1^st year after an ACS event follow. by 60 mg ×2/d for addit. 2 yrs.
C/I: Hypersens. Active pathology. bleed. History of intracran. haemorr. Severe hep. impair. Co-admin. with strong CYP3A4 inhib. (e.g., ketoconazole, clarithromycin, nefazodone, ritonavir, and atazanavir).

Corticosteroid. Budesonide 0.5 mg.
INHAL. SUSP: 20 (single dose). Initial: 1-2
mg, total dly dose. Child: 6 mths and
older: 0.25-0.5 mg total dly dose. Pts
on oral gluco-corticosteroids: Higher
start. dose: 1 mg total dly dose. Maint:
Titrate to lowest effect. dose: Range:
0.5-4 mg total dly dose. Severe cases:
May incr. further. Child 6 mths and
older: 0.25-2 mg total dly dose. Admin.
1-2 x dly.
Bronch. asth. when other ther. unsuit. or
insuffic.

Corticosteroid. Budesonide 1 mg.
INHAL. SUSP: 20 (single dose). Initial: 1-2
mg, total dly dose. Child: 6 mths and
older: 0.25-0.5 mg total dly dose. Pts
on oral gluco-corticosteroids: Higher
start. dose: 1 mg total dly dose. Maint:
Titrate to lowest effect. dose: Range:
0.5-4 mg total dly dose. Severe cases:
May incr. further. Child 6 mths and
older: 0.25-2 mg total dly dose. Admin.
1-2 x dly.
Bronch. asth. when other ther. unsuit. or
insuffic.